Literature DB >> 1697709

Variation of prostate-specific antigen expression in different tumour growth patterns present in prostatectomy specimens.

M P Gallee1, E Visser-de Jong, J A van der Korput, T H van der Kwast, F J ten Kate, F H Schroeder, J Trapman.   

Abstract

A series of 55 randomly chosen radical prostatectomy specimens was analyzed for expression of prostate-specific antigen (PSA) by immunohistochemical techniques. Tissue sections were selected in such a manner that in addition to glandular benign prostatic hyperplasia (BPH), one or more different prostatic tumour growth patterns were present. Four monoclonal antibodies, directed against three different PSA epitopes, and one polyclonal anti-PSA antiserum were used. Expression of PSA was compared with that of prostate-specific acid phosphatase (PAP), recognized by two different polyclonal antisera. A critical dilution aimed at a maximum of staining intensity on BPH tissue sections was chosen for all antibodies. Anti-PSA and anti-PAP antisera stained essentially all BPH samples (over 90%). Irrespective of the nature of the antibodies used, PSA expression was found to be decreased in prostatic carcinoma. A clear cut relationship was found between immunoreactivity for PSA and the degree of differentiation of the tumour area. Under the experimental conditions used the PSA monoclonal antibodies stained only 1 out of 10 undifferentiated carcinomas, whereas 50% to 70% of the well- and moderately-differentiated carcinomas showed immunoreactivity. This correlation was less pronounced with the PAP staining pattern. If the PSA antibody titer was raised the percentage of clearly staining undifferentiated carcinomas could be considerably increased (up to 60%-100%), indicating that PSA expression is not absent, but lowered in most (if not all) undifferentiated carcinomas.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1697709     DOI: 10.1007/bf00295844

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  30 in total

1.  The response of poorly differentiated prostatic tumors to staining for prostate specific antigen and prostatic acid phosphatase: a comparative study.

Authors:  J S Keillor; K Aterman
Journal:  J Urol       Date:  1987-05       Impact factor: 7.450

2.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.

Authors:  T A Stamey; N Yang; A R Hay; J E McNeal; F S Freiha; E Redwine
Journal:  N Engl J Med       Date:  1987-10-08       Impact factor: 91.245

3.  Classification of prostatic carcinomas.

Authors:  D F Gleason
Journal:  Cancer Chemother Rep       Date:  1966-03

4.  Changes in immunohistochemical staining in prostatic adenocarcinoma following diethylstilbestrol therapy.

Authors:  D Grignon; M Troster
Journal:  Prostate       Date:  1985       Impact factor: 4.104

5.  Immunochemical evaluation of the organ specificity of prostatic acid phosphatase.

Authors:  L M Shaw; N Yang; J J Brooks; M Neat; E Marsh; B Seamonds
Journal:  Clin Chem       Date:  1981-09       Impact factor: 8.327

6.  Evaluation of commercial immunoperoxidase kits in diagnosis of prostate carcinoma.

Authors:  M S Bentz; C Cohen; L R Budgeon; L M Demers
Journal:  Urology       Date:  1984-01       Impact factor: 2.649

7.  Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross-reacting antigen, beta-chorionic gonadotrophin, and prostate-specific antigen.

Authors:  D M Purnell; B M Heatfield; B F Trump
Journal:  Cancer Res       Date:  1984-01       Impact factor: 12.701

8.  Evaluation of prostate specific acid phosphatase and prostate specific antigen in identification of prostatic cancer.

Authors:  E P Allhoff; K H Proppe; C M Chapman; C W Lin; G R Prout
Journal:  J Urol       Date:  1983-02       Impact factor: 7.450

9.  Immunoperoxidase staining of acid phosphatase in human prostatic tissue.

Authors:  M C Lippert; H Bensimon; N Javadpour
Journal:  J Urol       Date:  1982-11       Impact factor: 7.450

10.  Monoclonal antibody (F5) to human prostate antigen.

Authors:  L D Papsidero; G A Croghan; M C Wang; M Kuriyama; E A Johnson; L A Valenzuela; T M Chu
Journal:  Hybridoma       Date:  1983
View more
  16 in total

Review 1.  Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients.

Authors:  Alessandro Conti; Matteo Santoni; Luciano Burattini; Marina Scarpelli; Roberta Mazzucchelli; Andrea B Galosi; Liang Cheng; Antonio Lopez-Beltran; Alberto Briganti; Francesco Montorsi; Rodolfo Montironi
Journal:  World J Urol       Date:  2015-12-22       Impact factor: 4.226

2.  Parameters of prostate cancer at contrast-enhanced ultrasound: correlation with prostate cancer risk.

Authors:  Guang Xu; Jian Wu; Ming-Hua Yao; Xu-Dong Yao; Bo Peng; Qing Wei; Hui-Xiong Xu; Rong Wu
Journal:  Int J Clin Exp Med       Date:  2015-02-15

3.  Prostate cancer incorrectly diagnosed as a rectal tumor: A case report.

Authors:  Zhi-Hua Liu; Chao Li; Liang Kang; Zhi-Yang Zhou; Sheng Situ; Jian-Ping Wang
Journal:  Oncol Lett       Date:  2015-04-03       Impact factor: 2.967

4.  Prostate cancer metastases to the rectum: a case report.

Authors:  Tariq O Abbas; Abdulla R Al-Naimi; Rafie A Yakoob; Issam A Al-Bozom; Abdulkader M Alobaidly
Journal:  World J Surg Oncol       Date:  2011-05-21       Impact factor: 2.754

5.  Stimulation of prostate cancer cellular proliferation and invasion by the androgen receptor co-activator ARA70.

Authors:  Yi Peng; Caihong X Li; Fei Chen; Zhengxin Wang; Martin Ligr; Jonathan Melamed; Jianjun Wei; William Gerald; Michele Pagano; Michael J Garabedian; Peng Lee
Journal:  Am J Pathol       Date:  2007-12-21       Impact factor: 4.307

6.  The mouse androgen receptor. Functional analysis of the protein and characterization of the gene.

Authors:  P W Faber; A King; H C van Rooij; A O Brinkmann; N J de Both; J Trapman
Journal:  Biochem J       Date:  1991-08-15       Impact factor: 3.857

7.  Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer.

Authors:  J A Ruizeveld de Winter; P J Janssen; H M Sleddens; M C Verleun-Mooijman; J Trapman; A O Brinkmann; A B Santerse; F H Schröder; T H van der Kwast
Journal:  Am J Pathol       Date:  1994-04       Impact factor: 4.307

8.  The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration.

Authors:  Jichao Qin; Xin Liu; Brian Laffin; Xin Chen; Grace Choy; Collene R Jeter; Tammy Calhoun-Davis; Hangwen Li; Ganesh S Palapattu; Shen Pang; Kevin Lin; Jiaoti Huang; Ivan Ivanov; Wei Li; Mahipal V Suraneni; Dean G Tang
Journal:  Cell Stem Cell       Date:  2012-05-04       Impact factor: 24.633

9.  Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma.

Authors:  Ming Yin; Rajiv Dhir; Anil V Parwani
Journal:  Diagn Pathol       Date:  2007-10-27       Impact factor: 2.644

10.  Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells.

Authors:  Xin Liu; Xin Chen; Kiera Rycaj; Hsueh-Ping Chao; Qu Deng; Collene Jeter; Can Liu; Sofia Honorio; Hangwen Li; Tammy Davis; Mahipal Suraneni; Brian Laffin; Jichao Qin; Qiuhui Li; Tao Yang; Pamela Whitney; Jianjun Shen; Jiaoti Huang; Dean G Tang
Journal:  Oncotarget       Date:  2015-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.